Burdziak Hubert, Syryło Tomasz, Grabińska Agnieszka, Burdziak Karol, Ławiński Janusz, Tomaka Monika, Zieliński Henryk
Department of Urology and Oncological Urology, Regional Hospital. St. Padre Pio in Przemysl, Przemyśl, Poland.
Department of Urology, Oncological and Functional Urology, Military Institute of Medicine in Warsaw, Warsaw, Poland.
Cent European J Urol. 2024;77(1):64-76. doi: 10.5173/ceju.2023.191. Epub 2024 Jan 13.
This study aimed to compare the safety and efficacy of treatment using simple prostatectomy (SP) and using photoselective vaporization of the prostate (PVP) with a 180W GreenLight XPS laser in patients with high-volume prostate hypertrophy.
The study included 120 patients with LUTS symptoms caused by prostatic enlargement of more than 80 ml; 79 patients were treated with SP, while 41 were treated with PVP. The analysis included subjective the International Prostate Symptom Score (IPSS) and Quality of Life (QoL), and objective (Qmax), (Qave), and post-void residual volume (PVR) parameters before treatment and at an average of 38 months after surgical treatment. Early and late adverse effects and length of hospitalisation were assessed. Complication reports were performed according to the modified Clavien-Dindo system.
The analysis independently showed the effectiveness of both methods. Subjective parameters (IPSS, QoL), showed no significant differences. Patients treated with SP scored slightly better on objective parameters (Qmax, Qave, and PVR). Analysis of adverse effects and hospitalisation time were more favourable after PVP.
SP and PVP were found to be comparable and highly effective in treating benign prostatic hyperplasia in terms of IPSS and QoL. Patients treated with the SP method obtained slightly better results of objective parameters such as Qmax, Qave, and PVR. Compared with SP, PVP has a more favourable safety profile.
本研究旨在比较单纯前列腺切除术(SP)和使用180W绿激光XPS激光进行前列腺光选择性汽化术(PVP)治疗大体积前列腺增生患者的安全性和有效性。
该研究纳入了120例因前列腺增大超过80ml而出现下尿路症状(LUTS)的患者;79例接受了SP治疗,41例接受了PVP治疗。分析内容包括主观的国际前列腺症状评分(IPSS)和生活质量(QoL),以及治疗前和手术治疗后平均38个月时的客观参数(最大尿流率Qmax、平均尿流率Qave)和残余尿量(PVR)。评估了早期和晚期不良反应以及住院时间。根据改良的Clavien-Dindo系统进行并发症报告。
分析独立显示了两种方法的有效性。主观参数(IPSS、QoL)无显著差异。接受SP治疗的患者在客观参数(Qmax、Qave和PVR)上得分略高。PVP治疗后的不良反应和住院时间分析结果更有利。
在IPSS和QoL方面,发现SP和PVP在治疗良性前列腺增生方面具有可比性且疗效显著。接受SP治疗的患者在Qmax、Qave和PVR等客观参数上取得了略好的结果。与SP相比,PVP具有更有利的安全性。